Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
Type:
Grant
Filed:
October 24, 2023
Date of Patent:
May 6, 2025
Assignees:
Virion Therapeutics, LLC, The Wistar Institute
Inventors:
Hildegund C J Ertl, Colin Stephen Magowan
Abstract: The present disclosure provides compounds, which in certain embodiments are ACSS2 inhibitors. In certain embodiments, the compounds of the disclosure are useful for treating, ameliorating, and/or preventing certain types of cancer.
Type:
Grant
Filed:
June 12, 2020
Date of Patent:
April 22, 2025
Assignee:
The Wistar Institute
Inventors:
Zachary Schug, Joseph Salvino, Valli Venkata Srikanth Yellamelli
Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.
Type:
Grant
Filed:
March 7, 2023
Date of Patent:
April 8, 2025
Assignees:
The Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
Abstract: The disclosure provides materials and methods for permanently labeling cells by transducing cells with viruses comprising a barcode. The disclosure is based on the idea that tracking, selecting and isolating lymphocytes labeled with the barcode can facilitate identification of clonal cells responsible for antibody or antibody fragment production.
Type:
Application
Filed:
September 30, 2024
Publication date:
April 3, 2025
Applicant:
The Wistar Institute of Anatomy and Biology
Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Ebolavirus glycoproteinimmunogens are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against Ebolavirus are disclosed. Method of preventing Ebolavirus and methods of treating individuals infected with Ebolavirus are disclosed. Consensus Ebolavirus proteins are disclosed.
Type:
Grant
Filed:
August 17, 2021
Date of Patent:
March 4, 2025
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
Abstract: Disclosed herein is a composition comprising a nucleic acid sequence encoding a Mayaro Virus antigen that elicits an immune response in a mammal. Also disclosed herein is a nucleic acid sequence encoding an anti-Mayaro Virus antibody, a fragment thereof, a variant thereof. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Mayaro virus infection in a subject using said composition and method of generation.
Type:
Grant
Filed:
October 12, 2018
Date of Patent:
January 14, 2025
Assignee:
The Wistar Institute of Anatomy and Biology
Inventors:
David B. Weiner, Kar Muthumani, Sagar Kudchodkar
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets CTLA-4. The disclosure also provides a method of preventing and/or treating disease, such as cancer, in a subject using the composition of the invention.
Type:
Grant
Filed:
October 3, 2018
Date of Patent:
January 14, 2025
Assignee:
The Wistar Institute of Anatomy and Biology
Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to chondroitin sulfate proteoglycan 4 (CSPG4) protein which is abundant in many cancers. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.
Type:
Grant
Filed:
August 1, 2019
Date of Patent:
January 14, 2025
Assignee:
The Wistar Institute of Anatomy and Biology
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an Ebola viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an Ebola virus infection in a subject using said composition and method of generation.
Type:
Grant
Filed:
September 17, 2018
Date of Patent:
December 10, 2024
Assignee:
The Wistar Institute of Anatomy and Biology
Abstract: The invention relates, in certain aspects, to developable forms of certain compounds that are useful to treat and/or prevent EBV infection and related conditions in a subject. The invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
Type:
Grant
Filed:
August 26, 2022
Date of Patent:
October 15, 2024
Assignee:
The Wistar Institute
Inventors:
Troy E. Messick, Paul M. Lieberman, Garry R. Smith, Arlindo L. Castelhano
Abstract: Provided herein are sequences of Plasmodium spp. liver stage exported proteins as well as expression constructs expressing the sequences. Also provided herein are methods for generating an immune response against malaria using the expression constructs provided herein.
Type:
Grant
Filed:
May 19, 2017
Date of Patent:
October 8, 2024
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
Inventors:
David Weiner, Emma Reuschel, Bernadette Ferraro, Ahmed S. I. Aly
Abstract: Disclosed herein are compositions comprising structurally modified DNA encoded antibodies (DMAbs), methods of structurally modifying DMAbs, and methods of using structurally modified DMAbs.
Type:
Grant
Filed:
May 10, 2018
Date of Patent:
August 6, 2024
Assignees:
The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
Inventors:
David Weiner, Ghiabe Guibinga, Neil Cooch, Charles Reed
Abstract: Therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1 and a PARP inhibitor. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.
Type:
Grant
Filed:
April 3, 2019
Date of Patent:
July 16, 2024
Assignee:
The Wistar Institut of Anatomy and Biology
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.
Type:
Grant
Filed:
December 23, 2021
Date of Patent:
May 14, 2024
Assignees:
The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
Inventors:
David Weiner, Trevor R F Smith, Kar Muthumani
Abstract: Disclosed herein are compositions and methods for treating and/or preventing cancer in mammals, and in particular, vaccines that treat and provide protection against tumor growth.
Type:
Grant
Filed:
June 7, 2018
Date of Patent:
April 2, 2024
Assignee:
The Wistar Institute of Anatomy and Biology
Abstract: Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV-Envelope (anti-ZIKV E) Protein antibody.
Type:
Grant
Filed:
September 19, 2017
Date of Patent:
March 12, 2024
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
Inventors:
David Weiner, Karuppiah Muthumani, Jian Yan
Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
Type:
Grant
Filed:
April 16, 2021
Date of Patent:
February 27, 2024
Assignee:
The Wistar Institute of Anatomy and Biology
Inventors:
Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets an immune checkpoint molecule. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
February 13, 2024
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals
Inventors:
David B. Weiner, Kar Muthumani, Niranjan Sardesai
Abstract: The present invention relates to compositions comprising two or more DNA plasmids encoding consensus and transmitted founder HIV envelope glycoproteins which expressed and induce a potent immune response.
Type:
Grant
Filed:
November 10, 2020
Date of Patent:
January 30, 2024
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology